The fate of bone after renal transplantation

Journal of Nephrology

Volumn 17, Issue 2, 2004, Pages 190-204

  Brandenburg, Vincent Matthias ^a   Westenfeld, Ralf ^a   Ketteler, Markus ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Bone mineral density; Fracture; Glucocorticoid induced osteoporosis; Hyperparathyroidism; Immunosuppression; Post transplantation bone disease; Renal osteodystrophy; Renal transplantation

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANTICONVULSIVE AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CLODRONIC ACID; CYCLOSPORIN A; ETIDRONIC ACID; GLUCOCORTICOID; HEPARIN; IBANDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; LOOP DIURETIC AGENT; MINERAL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; PREDNISOLONE; PREDNISONE; RISEDRONIC ACID; STEROID; TACROLIMUS; UNINDEXED DRUG; VITAMIN D DERIVATIVE; ZOLEDRONIC ACID;

BONE DENSITY; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE MINERAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; GRAFT REJECTION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MINERAL METABOLISM; MORBIDITY; NONHUMAN; OSTEODYSTROPHY; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BONE AND BONES; BONE DENSITY; BONE DISEASES; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 2942731404     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, Olschewski M, Schollmeyer PJ. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998; 66: 1004-8.
2. Parker CR, Freemont AJ, Blackwell PJ, Grainge MJ, Hosking DJ. Cross-sectional analysis of renal transplantation osteoporosis. J Bone Miner Res 1999; 14:1943-51.
3. Bellorin-Font E, Rojas E, Carlini RG, Suniaga O, Weisinger JR. Bone remodeling after renal transplantation. Kidney Int 2003; 85 (suppl): S125-8.
4. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002; 17: 2094-105.
5. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333: 166-74.
6. Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 2000; 13: 437-43.
7. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1922-8.
8. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (suppl. 3): S1-201.
9. Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003; 21: 318-26.
10. Bardin T. Musculoskeletal manifestations of chronic renal failure. Curr Opin Rheumatol 2003; 15: 48-54.
11. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33: 287-93.
12. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-21.
13. Setterberg L, Sandberg J, Elinder CG, Nordenstrom J. Bone demineralization after renal transplantation: contribution of secondary hyperparathyroidism manifested by hypercalcaemia. Nephrol Dial Transplant 1996; 11: 1825-8.
14. Torregrosa JV, Campistol JM, Montesinos M, Pons F, Martinez de Osaba MJ. Evolution of bone mineral density after renal transplantation: related factors. Nephrol Dial Transplant 1995; 10 (suppl 6): S111-3.
15. Bagni B, Gilli P, Cavallini A, Bagni I, Marzola MC, Orzincolo C, Wahner HW. Continuing loss of vertebral mineral density in renal transplant recipients. Eur J Nucl Med 1994; 21: 108-12.
16. D'Angelo A, Calo L, Giannini S, Carraro G, Bonfante L, Favaro S, Zaninotto M, Perin N, Di LD, Rigotti P, Antonello, A. Parathyroid hormone and bone metabolism in kidney-transplanted patients. Clin Nephrol 2000; 53: 19-22.
17. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant 2000; 14: 457-63.
18. Heaf JG. Bone disease after renal transplantation. Transplantation 2003; 75: 315-25.
19. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544-50.
20. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000; 11: 1093-9.
21. Rojas E, Carlini RG, Clesca P, Arminio A, Suniaga O, De Elguezabal K, Weisinger JR, Hruska KA, Bellorin-Font E. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 2003; 63: 1915-23.
22. Koch Nogueira PC, David L, Cochat P. Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 2000; 14: 342-6.
23. Messa P, Sindici C, Cannella G, Miotti V, Risaliti A, Gropuzzo M, Di LP, Bresadola F, Mioni G. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54: 1704-13.
24. Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12: 1530-7.
25. Brandenburg VM, Politt D, Ketteler M, Fassbender WJ, Heussen N, Westenfeld R, Freuding T, Floege J, Ittel TH. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 2004 (in press).
26. Torres A, Rodriguez AP, Concepcion MT, Garcia S, Rufino M, Martin B, Perez L, Machado M, de Bonis E, Losada M, Hernandez D, Lorenzo V. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998; 13 (suppl 3): S94-7.
27. Montalban C, De Francisco AL, Marinoso ML, Zubimendi JA, Unzueta MG, Amado JA, Arias M. Bone disease in long-term adult kidney transplant patients with normal renal function. Kidney Int 2003; 85 (suppl): S129-32.
28. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003; 23: 369-79.
29. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-8.
30. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17: 268-74.
31. Suwelack B, Gerhardt U, Witta J, Hillebrandt U, Hohage H. Effect of parathyroid hormone levels on carotid intima-media thickness after renal transplantation. Am J Hypertens 2001; 14: 1012-8.
32. Nakashima A, Yorioka N, Tanji C, Asakimori Y, Ago R, Usui K, Shigemoto K, Harada S. Bone mineral density may be related to atherosclerosis in hemodialysis patients. Osteoporos Int 2003; 14: 369-73.
33. Vautour LM, Melton LJ, III, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT. Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int 2004; 15: 160-7.
34. Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, Kestenbaum BR, Stehman-Breen C. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288: 3014-8.
35. Durieux S, Mercadal L, Orcel P, Dao H, Rioux C, Bernard M, Rozenberg S, Barrou B, Bourgeois P, Deray G, Bagnis CI. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 2002; 74: 496-500.
36. O'Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL. Risk factors for fractures in kidney transplantation. Transplantation 2002; 74: 362-6.
37. Patel S, Kwan JT, McCloskey E, McGee G, Thomas G, Johnson D, Wills R, Ogunremi L, Barron J. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 2001; 16: 1863-70.
38. Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, Agodoa LY, Duncan WE. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol 2001; 11: 450-7.
39. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999; 67: 1218-22.
40. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, Langman CB, Salinger MH, Sprague SM. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999; 14: 456-63.
41. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Ziegler R. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357: 342-7.
42. Lippuner K, Casez JP, Horber FF, Jaeger P. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab 1998; 83: 3795-802.
43. Isiklar I, Akin O, Demirag A, Niron EA. Changes in bone mineral density after renal transplantation. Transplant Proc 1998; 30: 814-5.
44. Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 1997; 63: 380-6.
45. Feber J, Cochat P, Braillon P, Castelo F, Martin X, Glastre C, Chapuis F, David L, Meunier PJ. Bone mineral density after renal transplantation in children. J Pediatr 1994; 125: 870-5.
46. Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P. Changes in bone mass early after kidney transplantation. J Bone Miner Res 1994; 9: 1-9.
47. Almond MK, Kwan JT, Evans K, Cunningham J. Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 1994; 66: 52-7.
48. Mikuls TR, Julian BA, Bartolucci A, Saag KG. Bone mineral density changes within six months of renal transplantation. Transplantation 2003; 75: 49-54.
49. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, Oberbauer R. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003; 63: 1130-6.
50. Kovac D, Lindic J, Kandus A, Bren AF. Prevention of bone loss with alendronate in kidney transplant recipients. Transplantation 2000; 70: 1542-3.
51. Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000; 57: 684-90.
52. Talalaj M, Gradowska L, Marcinowska-Suchowierska E, Durlik M, Gaciong Z, Lao M. Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant Proc 1996; 28: 3485-7.
53. Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, Schollmeyer PJ. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant 1995; 10: 2096-100.
54. El Agroudy AE, El Husseini AA, El Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 2003; 14: 2975-9.
55. Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD, Kim KR, Lee HC, Huh K, Lim SK. Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc 2000; 32: 1876.
56. Brandenburg VM, Ketteler M, Fassbender WJ, Heussen N, Freuding T, Floege J, Ittel TH. Development of lumbar bone mineral density in the late course after kidney transplantation. Am J Kidney Dis 2002; 40: 1066-74.
57. Ugur A, Guvener N, Isiklar I, Karakayali H, Erdal R. Efficiency of preventive treatment for osteoporosis after renal transplantation. Transplant Proc 2000; 32: 556-7.
58. Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc 2002; 34: 2111-3.
59. Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996; 28: 105-14.
60. Cruz DN, Wysolmerski JJ, Brickel HM, Gundberg CG, Simpson CA, Mitnick MA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Parameters of high bone-turnover predict bone loss in renal transplant patients: a longitudinal study. Transplantation 2001; 72: 83-8.
61. Casez JP, Lippuner K, Horber FF, Montandon A, Jaeger P. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002; 17: 1318-26.
62. Fan SL, Kumar S, Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int 2003; 63: 2275-9.
63. Arlen DJ, Lambert K, Ioannidis G, Adachi JD. Treatment of established bone loss after renal transplantation with etidronate. Transplantation 2001; 71: 669-73.
64. Ahlborg HG, Johnell O, Nilsson BE, Jeppsson S, Rannevik G, Karlsson MK. Bone loss in relation to menopause: a prospective study during 16 years. Bone 2001; 28: 327-31.
65. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 875-83.
66. Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiebaud D, Burckhardt P. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 2001; 12: 112-6.
67. Valimaki MJ, Kinnunen K, Tahtela R, Loyttyniemi E, Laitinen K, Makela P, Keto P, Nieminen M. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Osteoporos Int 1999; 10: 128-36.
68. Hardinger KL, Ho B, Schnitzler MA, Desai N, Lowell J, Shenoy S, Chapman W, Crippin JS. Serial measurements of bone density at the lumbar spine do not predict fracture risk after liver transplantation. Liver Transpl 2003; 9: 857-62.
69. Yazawa K, Ishikawa T, Ichikawa Y, Shin J, Usui Y, Hanafusa T, Fukunishi T, Sakai R, Nagano S, Fujita N, Mizuno K. Positive effects of kidney transplantation on bone mass. Transplant Proc 1998; 30: 3031-3.
70. Giannini S, D'Angelo A, Carraro G, Antonello A, Di Landro D, Marchini F, Plebani M, Zaninotto M, Rigotti P, Sartori L, Crepaldi G. Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol 2001; 56: 353-63.
71. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996; 312: 1254-9.
72. Caglar M, Adeera L. Factors affecting bone mineral density in renal transplant patients. Ann Nucl Med 1999; 13: 141-5.
73. Grotz WH, Mundinger FA, Muller CB, Rasenack J, Schulte-Monting J, Langer MF, Schollmeyer PJ. Trabecular bone architecture in female renal allograft recipients - assessed by computed tomography. Nephrol Dial Transplant 1997; 12: 564-69.
74. Parfitt AM. Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 1992; 13 (suppl 2): S41-7.
75. Wolpaw T, Deal CL, Fleming-Brooks S, Bartucci MR, Schulak JA, Hricik DE. Factors influencing vertebral bone density after renal transplantation. Transplantation 1994; 58: 1186-9.
76. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-7.
77. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003; 15: 454-7.
78. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 2003; 32: 135-57.
79. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-87.
80. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966: 73-81.
81. McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant 1995; 9: 20-4.
82. Epstein S. Cyclosporin A: friend or foe? Calcif Tissue Int 1991; 49: 232-4.
83. Westeel FP, Mazouz H, Ezaitouni F, Hottelart C, Ivan C, Fardellone P, Brazier M, El E, I, Petit J, Achard JM, Pruna A, Fournier A. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int 2000; 58: 1788-96.
84. Epstein S, Dissanayake IR, Goodman GR, Bowman AR, Zhou H, Ma Y, Jee WS. Effect of the interaction of parathyroid hormone and cyclosporine a on bone mineral metabolism in the rat. Calcif Tissue Int 2001; 68: 240-7.
85. Sass DA, Bowman AR, Yuan Z, Ma Y, Jee WS, Epstein S. Alendronate prevents cyclosporin A-induced osteopenia in the rat. Bone 1997; 21: 65-70.
86. Cueto-Manzano AM, Konel S, Crowley V, France MW, Freemont AJ, Adams JE, Mawer B, Gokal R, Hutchison AJ. Bone histopathology and densitometry comparison between cyclosporine A monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation 2003; 75: 2053-8.
87. El Haggan W, Barthe N, Vendrely B, Chauveau P, Berger F, Aparicio, M, Potaux L. One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine. Transplant Proc 2002; 34: 1817-8.
88. Goodman GR, Dissanayake IR, Sodam BR, Gorodetsky E, Lu J, Ma YF, Jee WS, Epstein S. Immunosuppressant use without bone loss - implications for bone loss after transplantation. J Bone Miner Res 2001; 16: 72-8.
89. Goffin E, Devogelaer JP, Depresseux G, Squifflet JP, Pirson Y, van Yperselede dS. Evaluation of bone mineral density after renal transplantation under a tacrolimus-based immunosuppression: a pilot study. Clin Nephrol 2003; 59: 190-5.
90. van den Ham EC, Kooman JP, Christiaans ML, van Hooff JP. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transpl Int 2003; 16: 82-7.
91. Dissanayake IR, Goodman GR, Bowman AR, Ma Y, Pun S, Jee WS, Epstein S. Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1998; 65: 275-8.
92. Kokado Y, Takahara S, Ichimaru N, Toki K, Kyo M, Permpongkosol S, Kojima Y, Inoue T, Wang JD, Okuyama A. Factors influencing vertebral bone density after renal transplantation. Transpl Int 2000; 13 (suppl 1): S431-5.
93. Torres A, Machado M, Concepcion MT, Martin N, Lorenzo V, Hernandez D, Rodriguez AP, Rodriguez A, de BE, Gonzalez-Posada JM, Hernandez A, Salido E. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int 1996; 50: 1726-33.
94. Eriksen EF. Primary hyperparathyroidism: lessons from bone histomorphometry. J Bone Miner Res 2002; 17 (suppl 2): N95-7.
95. Silverberg SJ, Shane E, del C, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty, M, Parisien MV. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4: 283-91.
96. Brandenburg VM, Fassbender WJ, Floege J, Freuding T, Ittel TH. Protective factors for an increase of the lumbar BMD early after renal transplantation (abstract). Osteologie 2001; 10: 74.
97. Rubin MR, Bilezikian JP. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002; 87: 4033-41.
98. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
99. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 1994; 58: 912-5.
100. Parker CR, Freemont AJ, Blackwell PJ, Grainge MJ, Hosking DJ. Cross-sectional analysis of renal transplantation osteoporosis. J Bone Miner Res 1999; 14: 1943-51.
101. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003; 14: 77-81.
102. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000; 15: 944-51.
103. Briner VA, Thiel G, Monier-Faugere MC, Bognar B, Landmann J, Kamber V, Malluche HH. Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. Transplantation 1995; 59: 1393-400.
104. Black DM, Cummings SR, Karpf DB, CauleyJA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
105. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
106. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6.
107. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-6.
108. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003; 14: 2-12.
109. Marcus R, Wong M, Heath H, III, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002; 23: 16-37.
110. Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18: 919-24.
111. Loddenkemper K, Grauer A, Burmester GR, Buttgereit F. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases. Clin Exp Rheumatol 2003; 21: 19-26.
112. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496-503.
113. Berczi C, Asztalos L, Kincses Z, Balogh A, Locsey L, Balazs G, Lukacs G. Comparison of calcium and alfacalcidol supplement in the prevention of osteopenia after kidney transplantation. Osteoporos Int 2003; 14: 412-7.
114. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669-76.
115. Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant 2002; 2: 62-7.
116. Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R, Hutchison AJ. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 2000; 35: 227-36.
117. Giannini S, Dangel A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle CL, Sartori L, Crepaldi G. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001; 16: 2111-7.
118. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003; 76: 1498-502.
119. Torregrosa JV, Moreno A, Gutierrez A, Vidal S, Oppenheimer F. Alendronate for treatment of renal transplant patients with osteoporosis. Transplant Proc 2003; 35: 1393-5.
120. Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int 2004; 65: 304-9.
121. Torres A, Garcia S, Gomez A, Gonzalez A, Barrios Y, Concepcion MT, Hernandez D, Garcia JJ, Checa MD, Lorenzo V, Salido E. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004; 65: 705-12.
122. Ippoliti G, Pellegrini C, Campana C, Rinaldi M, D'Armini A, Goggi C, Aiello M, Vigano M. Clodronate treatment of established bone loss in cardiac recipients: a randomized study. Transplantation 2003; 75: 330-4.
123. Rodd C. Bisphosphonates in dialysis and transplantation patients: efficacy and safety issues. Perit Dial Int 2001; 21 (suppl 3): S256-60.
124. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.8. Bone disease. Nephrol Dial Transplant 2002; 17 (suppl 4): S43-8.
125. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD. Collapsing focal segmental glomerulosclerosis, following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-72.
126. Velasquez-Forero F, Mondragon A, Herrero B, Pena JC. Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant 1996; 11 (suppl 3): S58-64.
127. Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, Adams JE, Mawer B, Gokal R. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int 1999; 55: 2021-9.
128. Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, Bellorin-Font E. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000; 36: 160-6.
129. Carlini RG, Rojas E, Arminio A, Weisinger JR, Bellorin-Font E. What are the bone lesions in patients with more than four years of a functioning renal transplant? Nephrol Dial Transplant 1998; 13 (suppl 3): S103-4.
130. Cochat P, Braillon P, Feber J, Hadj-Aissa A, Dubourg L, Liponski I, Said MH, Glastre C, Meunier PJ, David L. Body composition in children with renal disease: use of dual energy X-ray absorptiometry. Pediatr Nephrol 1996; 10: 264-8.
131. Hernandez E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, Martinis R, Bellorin-Font E, Weisinger JR. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 2003; 63: 2269-74.
132. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002; 162: 537-40.
133. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004; 19: 19-24.
134. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Domenig C, Zsontsich T, Klaushofer K, Delling G, Oberbauer R. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002; 39: 580-6.